Abstract
Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 9-20 |
| Number of pages | 12 |
| Journal | Current Neurology and Neuroscience Reports |
| Volume | 3 |
| Issue number | 1 |
| State | Published - Jan 2003 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
- Neuroscience(all)
Cite this
Neuroprotective agents for the treatment of acute ischemic stroke. / Ovbiagele, Bruce; Kidwell, Stella; Starkman, Sidney; Saver, Jeffrey L.
In: Current Neurology and Neuroscience Reports, Vol. 3, No. 1, 01.2003, p. 9-20.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neuroprotective agents for the treatment of acute ischemic stroke
AU - Ovbiagele, Bruce
AU - Kidwell, Stella
AU - Starkman, Sidney
AU - Saver, Jeffrey L.
PY - 2003/1
Y1 - 2003/1
N2 - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
AB - Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
UR - http://www.scopus.com/inward/record.url?scp=0042888736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042888736&partnerID=8YFLogxK
M3 - Article
C2 - 12507405
AN - SCOPUS:0042888736
VL - 3
SP - 9
EP - 20
JO - Current Neurology and Neuroscience Reports
JF - Current Neurology and Neuroscience Reports
SN - 1528-4042
IS - 1
ER -